Tag:
bardoxolone
Latest Headlines
Latest Headlines
AbbVie celebrates New Year's Day as a big new biopharma player
After 15 months of planning, AbbVie has split away from Abbott, complete with a pipeline of more than 20 mid- and late-stage therapies, $18 billion in revenue and a commercial operation that spans the globe.
Abbott slammed after deaths scuttle blockbuster PhIII kidney disease program
The termination of the BEACON study is a major setback for Abbott Laboratories, which had invested huge sums in bardoxolone and a second-generation portfolio that had been expected to provide its pharma spinout with blockbuster revenue.
UPDATED: Abbott bets $400M on mega-blockbuster future for Reata program
Abbott ( $ABT ) has essentially doubled down on its high-stakes gamble that Reata Pharmaceuticals has the inside track on improving renal function in patients with chronic kidney disease, agreeing to
Abbott spotlights blockbuster hopefuls in pitching spinoff
Abbott Labs' pharma-designated CEO, Richard Gonzalez, spent a good part of Friday painting a bright future for Abbott's proposed spinoff. Abbott, of course, already has a multibillion-dollar
Abbott deals beef up late-stage platform of blockbuster contenders
Abbott Labs ( $ABT ) doesn't do a lot of deals compared with some of its Big Pharma rivals. But when the company inks a deal, it isn't afraid of using some big numbers. Abbott pledged $450 million just
Reata scores $450M in quick cash from Abbott pact
Irving, TX-based Reata Pharmaceuticals snared a treasure trove of $450 million in upfront and near-term cash from Abbott Labs in exchange for the ex-U.S. licensing rights to the mid-stage chronic
